US 11,951,148 B1Granted

Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof

AssigneeFleurir Abx LLC

InventorJohn Lee Pace

Life of this patent

Estimating the term…

Loading patent…

Abstract

New improved formulations are described, comprising at least one composition, with or without another composition (at least one second composition), in which the at least one composition, a first composition, is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The at least one second composition may be a streptogramin. The first composition, alone or in combination with another, may be used to improve and/or treat a wide variety of bacterial infections, providing, on its own better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other or alternative inhibitors of lipid A deacetylase, as well as no expected cardiotoxicity. When provided to a susceptible microorganism as a combination described herein, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations). Such combinations may also be provided via any route(s) of administration, and in any pharmaceutically acceptable form known, available, and/or suitable for use, such as to a subject in need thereof.

Claims13

Dependent claims

A composition for utilization in a subject in need thereof having or suspected of having an aerobic bacteria susceptible to the composition, the composition comprising:

an effective amount of an inhibitor of lipid A deacetylase, the inhibitor being one that inhibits lipid A deacetylase in the aerobic bacteria, and the effective amount of the inhibitor causing permeabilization of an outer membrane of the aerobic bacteria thereby compromising integrity of the aerobic bacteria,
wherein the composition comprising the effective amount of the inhibitor is a pharmaceutically acceptable form of the composition and in a form suitable for administration of the composition to the subject in need thereof, the composition optionally including one or more pharmaceutically acceptable excipients for administration of the composition,
wherein the composition, when causing permeabilization of the outer membrane of the aerobic bacteria, inhibits or prevents formation of the outer membrane of the aerobic bacteria,
wherein the aerobic bacteria is one or more aerobic bacteria causing or suspected of causing an infection in the subject in need thereof,
wherein the aerobic bacteria is Gram-negative and is targeted by the composition,
wherein the composition is in the form of at least one of Formula I, Formula II, and Formula III, or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, in which Formula I is:
and Formula II is:
and Formula III is:
wherein R1 is any one of:
wherein R2 is any one of:
and wherein R3 is any one or more of:

8 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/498,647Filed 11 Oct 2021 · continuation
Priority: 14 Mar 2014
Granted: 9 Apr 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/0073
Pulmonary tract; Aromatherapy: sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Family

Application61/953,721Us provisional application · filed 14 Mar 2014
Application14/659,609Parent of this continuation · filed 16 Mar 2015
Application15/401,085Parent of this continuation · filed 8 Jan 2017
US 9,539,305 B1Parent of this continuation · filed 10 Jan 2017
Application15/877,338Parent of this continuation · filed 22 Jan 2018
US 9,872,884 B1Parent of this continuation · filed 23 Jan 2018
Application16/429,519Parent of this continuation · filed 3 Jun 2019
US 10,307,457 B1Parent of this continuation · filed 4 Jun 2019
US 11,141,453 B1Parent of this continuation
US 11,951,148 B1This patent

From the US filing history. Foreign family members aren’t listed.